GlassScriptPhysician profile
Holly E Azimi
NPI 1487022273
$7,570.03
in general payments reported to CMS, 2019-2025
33 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,030 · 2022: $1,532 · 2023: $1,347 · 2024: $1,243 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,950 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,950.19 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,870.16 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,150.08 | 2021-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $841.03 | 2021-2025 | Ofev, Jascayd |
| Insmed, INC. | $618.78 | 2021-2025 | Arikayce, Brinsupri |
| Janssen Pharmaceuticals, INC | $411.72 | 2021-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $320.58 | 2021-2022 | |
| United Therapeutics Corporation | $303.92 | 2022-2025 | Tyvaso, Tyvaso, Remodulin |
| Grifols USA, LLC | $247.17 | 2021-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $232.37 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $208.74 | 2021-2025 | Glassia, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $137.02 | 2023-2025 | Dupixent |
| Verona Pharma, INC. | $112.05 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $100.42 | 2024-2025 | Winrevair, Keytruda |
| Mylan Specialty L.P. | $99.57 | 2022 | |
| Argenx US, INC. | $97.72 | 2023 | Vyvgart |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $93.54 | 2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $80.45 | 2021-2024 | |
| Amgen INC. | $73.49 | 2022-2024 | Tezspire |
| Harmony Biosciences LLC | $68.98 | 2022-2023 | Wakix |
| Ani Pharmaceuticals, INC. | $65.83 | 2024 | Purified Cortrophin Gel |
| Abbvie INC. | $58.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Daiichi Sankyo INC. | $48.48 | 2023-2024 | Injectafer |
| Electromed, INC. | $41.26 | 2024-2025 | Smartvest |
| Baxter Healthcare | $38.41 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $35.81 | 2021-2024 | |
| Inspire Medical Systems, INC. | $34.94 | 2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $31.38 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.38 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.36 | 2022 | |
| La Jolla Pharmaceutical Company | $16.61 | 2022 | |
| Tactile Systems Technology INC | $16.49 | 2023 | Flexitouch Plus, Entre Plus |
| Teva Pharmaceuticals USA, INC. | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Azimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.